Work

Cabozantinib (XL184) At 40 Mg in Patients with Metastatic Castration Resistant Prostate Cancer (MCRPC): Results of a Phase 2 Non-Randomized Expansion Cohort (NRE)

Year: 2012

Type: article

Source: Annals of Oncology

DOI: 10.1016/s0923-7534(20)33492-x

Authors: J.S. de Bono, M.R. Smith, D. Rathkopf, P.G. Corn, D. Mukherji, A.L. Harzstark, O.A. Sartor, D.C. Smith, N. Tunariu, C. Sweeney

Institutions: Institute of Cancer Research, Royal Marsden Hospital, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, University of California, San Francisco, Tulane University, University of Michigan, Royal Marsden NHS Foundation Trust, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3000363219

FWCI: 1.545

Cites:

Cited by: 7

Related to: 10